A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Vibegron (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Urovant Sciences
Most Recent Events
- 11 Sep 2023 According to a Sumitomo Pharma media release, results from this trial will be presented at future medical congresses.
- 11 Sep 2023 Results presented in the Sumitomo Pharma Media Release.
- 23 Aug 2022 Status changed from active, no longer recruiting to completed.